![IMBRUVICA® is the the ONLY BKTi currently recommended in European guidelines for R/R MCL[^1] [^1]: McKay P, <em>et al.</em> Guideline for the management of mantle cell lymphoma. <em>Br J Haematol.</em> 2018;182:46–62.](https://eu-images.contentstack.com/v3/assets/blt6b8ca7f1bf9e5733/blt6df852c40a76b4c4/636ba8ae140ac93269ab25c0/hero_banner_1.jpg?width=1920&height=360&format=webp&quality=50)
IMBRUVICA® is the the ONLY BKTi currently recommended in European guidelines for R/R MCL[1]
Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy and represents 6%–8% of malignant lymphoma in Western Europe.[2]
IMBRUVICA® is recommended in treatment guidelines[1][2][3]
IMBRUVICA® is recommended by the ESMO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) and British Journal of Haematology (BJH) guidelines for the treatment of R/R MCL.[1][2][4]
The BJH guideline was compiled according to the British Society for Haematology process.[1]
Targeted approaches such as IMBRUVICA® should be considered in relapsed, particularly early relapsed, or refractory MCL.[1]
Read more about IMBRUVICA®'s key role in the treatment of R/R MCL in the British Journal of Haematology’s clinical practice guidelines for diagnosis, treatment and follow-up.
Experience and trust for patients with B-cell malignancies[5]
Over 250,000 patients with B-cell malignancies have been treated with IMBRUVICA® worldwide.[5]†
IMBRUVICA® disrupts 3 key drivers of B-cell malignancy[6][7][8][9][10][11][12]
IMBRUVICA® inhibits BTK and causes its irreversible inactivation by preventing the signalling cascades within cells from being activated, promoting the inhibition of cell proliferation and apoptosis of cancer cells.[6][13]
IMBRUVICA® is a BTK inhibitor that forms a covalent bond with a cysteine residue (Cys-481) in the BTK active site, leading to sustained inhibition of BTK enzymes.[6]
This content is intended for Healthcare Professionals only. IMBRUVICA® is licensed in the following indications:
- IMBRUVICA® as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
- IMBRUVICA® as a single agent or in combination with rituximab or obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
- IMBRUVICA® as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
- IMBRUVICA® as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemoimmunotherapy.
- IMBRUVICA® in combination with rituximab is indicated for the treatment of adult patients with WM.
*Of licensed agents.
†Includes patients with different types of B-cell malignancies.[6]
BJH=British Journal of Haematology; BTKi=Bruton’s tyrosine kinase inhibitor; CLL=chronic lymphocytic leukaemia; DGHO=Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie; ESMO=European Society for Medical Oncology; MCL=mantle cell lymphoma; R/R=relapsed/refractory; WM=Waldenström’s macroglobulinaemia.
This site has been developed by J&J-Cilag International NV. J&J-Cilag International NV is the responsible editor of this document.
| Adverse events should be reported. Reporting an adverse event will help J&J monitor the safety of all our healthcare products for the benefit of patients and consumers. It is important to report adverse events, even if it is a known adverse event, as this provides valuable information for monitoring product safety, allowing J&J to provide up-to-date information in the Summary of Product Characteristics and product information leaflets. For Adverse Events or safety related issues on J&J products, please approach the mailbox PVNEMA@ITS.JNJ.COM or Tel: +961 1 518769/ +961 1 518775 |
